Whether your life science organization is growing or already well-established, you understand the importance of risk management in product development. For both compliance and product fidelity, you need to be sure as much risk as possible is designed out of your product.
However, it seems like there are millions of risk management tools and activities out there. How do you know which ones will prove the most beneficial? While the answer is mostly dependent on your organization’s capacities and needs, there are four particular risk management tools that you should think about adopting. Not only are they widely used across the industry, but some are also recommended in FDA guidance.
Failure Mode Effects Analysis (FMEA) is a well-proven risk management tool. FMEA activities help your development teams evaluate possible failure modes of a given process and the resulting impacts on your product and/or users. Particularly suitable for evaluating and controlling process risks, this risk tool breaks down risk analysis for complex systems into manageable steps. As a result, your risk management teams can identify and develop mitigations for elements and operations within your product’s system that could otherwise compromise safety and effectiveness.
Conducting FMEA exercises can be most constructive early in the development process. By looking at early-stage failure modes—known, predicted, or otherwise—the resulting controls can be applied to the product design. While FMEAs should be done throughout the development process and into the postmarket environment, their value in early-stage development is worth keeping in mind.
FTAs are particularly practical in risk management because they offer a graphical way of understanding faults and failures related to your product’s design. While most risk tools present data in matrices, FTAs show a top-down informational trace. Your risk teams can use the tool for more rapid understanding of event sequences that both lead to failures and influence related hazards. When paired with other risk management tools, FTAs can be a highly effective way of assessing and controlling risk in your product.
Use Error Analysis (UEA) helps your risk teams scope out these factors and connect them to potential use errors. From the data the UEA generates, you can identify mitigations, develop risk controls, and re-evaluate for any residual risk. The ability to assess a multitude of influencing factors is what makes the UEA particularly powerful for life science risk management; by seeing all the pieces that could contribute to use error, more dynamic risk controls can be developed and implemented. While it’s impossible to control for all usability risks, the UEA brings use error that much more under control.
When conducting PHA activities, the emphasis is on understanding either known or anticipated hazards. You can generate these hazards through postmarket data, logical reasoning, or otherwise. Like all risk tools, it’s important to run through iterative PHA exercises because knowledge of all possible hazards is inherently limited. However, applying information that’s already available or predictable/foreseeable can help in coming up with pragmatic risk controls early in development.
While these four risk management tools are helpful on their own, using just one of them may not be adequate for all your risk management needs. Instead, consider using multiple risk tools that can interface well together. For example, conducting FTA exercises on use errors identified through UEA activities can illuminate the root cause of that error and where in the user-product interface risk controls would be most valuable. Such combinations of tools not only make your risk management more dynamic, but help you work toward a safer, more effective product.